Presently insiders own 0.4% shares in Gilead Sciences. In the past 6 months, insider ownership in the company has dropped by 27.28%. On September 2nd, CFO Robin L. Washington had sold 6,250 shares of the stock.
Over the last month, the company’s stock has fallen by 4.28%. And over the past three months, the stock has seen a drop of 7.56%.
Nonetheless, the company remains a top pick among biotechnology analysts. According to TipRanks, all nine analysts who rated Gilead in the last three months offered bullish ratings. The average 12-month price target between the nine analysts is $130.88, marking a 20% potential upside from current levels.